Open AccessFLABRA, frontline approach for BRCA testing in an ovarian cancer population: a Latin America epidemiologic study
Author(s) -
Gonzalo Giornelli,
Dolores Gallardo,
Roberto Hegg,
G. Gomez Abuin,
Máximo de la Vega,
Maria Lim-Law,
Valeria Cáceres,
Lina María Trujillo,
Maria Del Pilar Estevez-Diz,
Cristian Pacheco,
Leonardo Sganga,
Susana Goncalves
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2020-1152
Subject(s) - medicine , germline , ovarian cancer , germline mutation , oncology , latin americans , genetic counseling , genetic testing , gynecology , cancer , population , mutation , genetics , biology , environmental health , linguistics , philosophy , gene
Aim: FLABRA evaluated the prevalence of BRCA mutations, genetic counseling and management approaches in patients with ovarian cancer in Latin America. Patients & methods: Patients with ovarian cancer from six Latin–American countries were enrolled. Tumor samples were tested for BRCA mutations ( BRCA mut ). In cases with BRCA mut , blood samples were analyzed to determine germline versus somatic mutations. Medical records were reviewed for counseling approach and treatment plan. Results: From 472 patients enrolled, 406 samples yielded conclusive results: 282 were BRCA wild-type ( BRCA wt ), 115 were BRCA mut and nine were variants of uncertain significance. In total, 110/115 were tested for germline mutations (77 germline and 33 somatic). Conclusion: Tumor testing to identify mutations in BRCA1/2 in ovarian cancer can help optimize treatment choices, meaning fewer patients require germline testing and genetic counseling, a scant resource in Latin America. Clinical trial registration: NCT02984423 ( ClinicalTrials.gov )